Canada Spends Logo

Explore our Budget 2026 analysis

Grant: Master's Award: Canada Graduate Scholarships

University of British Columbia

$17,500.00

A Novel Combination of Antibody-Targeted Radiotherapy and Immunotherapy for the Treatment of Advanced Pancreatic Ductal Adenocarcinoma

FY 2013-14

Summary
Pancreatic cancer is one of the deadliest cancers with only 8% of patients surviving 5 years. The reason is that the cancer cells have often already spread or metastasized at the time of detection; it is almost impossible using conventional chemotherapy and radiation therapy to reach and treat them all. To try to improve this delivery problem, we plan to test the use of an antibody fragment, called an ""scFv"", to deliver a novel combination therapy directly to cancer cells in the main tumor and also in metastases. This antibody fragment will not only carry a radioactive isotope to kill the tumors, but also a molecule called a ""TLR9 agonist"" that can activate the body's own immune system to fight the cancer. Although either therapy approach can only induce an incomplete tumor response, there is significant preliminary data that indicates that the combination of both might be powerful enough to overcome the cancer's defence against treatment.
Program
Master's Award: Canada Graduate Scholarships
Location
British Columbia, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database

As published

Id
311746
Name
Esposito Tullio V
Region
British Columbia
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
A Novel Combination of Antibody-Targeted Radiotherapy and Immunotherapy for the Treatment of Advanced Pancreatic Ductal Adenocarcinoma
Programtype2
Studentship Programs
Orgnameinp2
University of British Columbia
Cihramount2
$17,500
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Cpg Oligodeoxynucleotide (Odn); Mesothelin; Pancreatic Ductal Adenocarcinoma; Radioimmunotherapy; Rhenium 188; Single Chain Fragment Variable (Scfv); Toll ­Like Receptor (Tlr) 9 Agonist
Abstract
Pancreatic cancer is one of the deadliest cancers with only 8% of patients surviving 5 years. The reason is that the cancer cells have often already spread or metastasized at the time of detection; it is almost impossible using conventional chemotherapy and radiation therapy to reach and treat them all. To try to improve this delivery problem, we plan to test the use of an antibody fragment, called an ""scFv"", to deliver a novel combination therapy directly to cancer cells in the main tumor and also in metastases. This antibody fragment will not only carry a radioactive isotope to kill the tumors, but also a molecule called a ""TLR9 agonist"" that can activate the body's own immune system to fight the cancer. Although either therapy approach can only induce an incomplete tumor response, there is significant preliminary data that indicates that the combination of both might be powerful enough to overcome the cancer's defence against treatment.
Competitiondate
201312
Approvedterm2
1 yr 0 mth
Pinamesdelim
Esposito, Tullio V
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $17,500~ $0~